Funding · Healthcare & Life Sciences

Genexis Biotech raises seed funding for protein platform

By Startup Enthusiast · 11 March 2026

What they do

Genexis Biotech uses precision fermentation to produce recombinant proteins for research and pharma

It raised over $457K in seed funding and earlier got support from Indigram Labs Foundation

The startup aims to localise production of specialised proteins currently imported into India at high cost

Genexis Biotech is a deep-tech startup that uses advanced fermentation technologies to produce recombinant proteins.
Its core technology is precision fermentation, using microorganisms like yeast and bacteria as biological factories.
The company has worked on 15-20 proteins across different platforms.
It raised over $457K in seed funding, with early support from Indigram Labs Foundation.
Earlier funding came from personal savings and revenue from supplying proteins to government labs during the COVID-19 pandemic.

The startup's fermentation yields are nearly 20 times higher than traditional industry benchmarks.
Its success rate in protein development projects is 60-70%.
Genexis aims to localise production of specialised proteins currently imported into India at high cost.

Genexis Biotech is a deep-tech startup focused on advanced fermentation technologies and recombinant protein production.
Its core technology is precision fermentation, using microorganisms (yeast, bacteria, cell culture) as biological factories.
The platform produces multiple recombinant proteins; it has worked on 15-20 proteins across platforms.
Fermentation protein yields are nearly 20 times higher than traditional industry benchmarks.
The company follows a market-driven innovation approach, identifying proteins with commercial demand and ethical value.
It has a multi-tiered market strategy: Research Use Only proteins, GMP-grade for pharma, and regulatory-approved for global markets.
The goal is to localise production of specialised proteins currently imported into India at high cost.

Indigram Labs Foundation (existing) — Early supporter that introduced the startup to deep-tech investors.

Product: Animal-origin-free recombinant proteins and enzymes made with precision fermentation.
Customers: Biopharma, food-tech, and cell culture companies.
How it makes money: Develops and sells recombinant biomolecules through B2B supply and partnerships.
What sets it apart: Uses precision fermentation and operates a certified Class 10,000 facility.
Operations: Scaling bioreactor capacity and building downstream processing infrastructure.